NCT07152379Phase 2Not yet recruiting

Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2030-09-30Estimated

Enrollment · participants25Estimated

Source updated2026-09-22Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-22 · 2 fields changed

Planned enrollment increased by 15 participants

− Before

~~10 participants (planned)~~

+ After

25 participants (planned)

Primary completion date changed

− Before

~~1 Oct 2027~~

+ After

30 Sep 2030

Check registry source

Study details

Conditions studied

Transfusion Reaction, Hemolytic

Treatments or interventions studied

Not recorded

Primary outcomes · main study measures

Read the study measures

measure: Acute or delayed hemolytic transfusion reactions; description: Incidence of acute or delayed hemolytic transfusion reactions (AHTR or DHTR) attributed to the study INTERCEPT RBC transfusion, based upon clinical and/or laboratory findings, using Centers for Disease Control (CDC) Hemovigilance criteria.; timeFrame: 90 days; measure: Clearance; description: Incidence of rapid clearance (complete clearance by Day 30) of INTERCEPT RBCs assessed by flow cytometry.; timeFrame: 30 days

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history